Court Unseals Key Evidence in Coventry Filing Showing Abacus Global Management Relied on Short Lapetus Life Expectancy Estimates and Misled Investors

Article content

Lapetus Filings With the Florida Office of Insurance Regulation Reveal an Alarmingly Low 41.5% Actual-to-Expected Ratio 

Article content

Abacus Misled Its Investors by Concealing Critical Facts About the Lewis & Ellis Valuation Report It Had Commissioned

Article content

Article content

FORT WASHINGTON, Pa., Aug. 04, 2026 (GLOBE NEWSWIRE) — Coventry First LLC (“Coventry”) and its Co-Founder and Executive Chairman, Alan H. Buerger, secured a significant ruling in their ongoing litigation with Abacus Global Management Inc. (“Abacus”) (NYSE: ABX). On July 29, 2026, the U.S. District Court for the Middle District of Florida ordered the unsealing of a number of key documents that Abacus has tried to keep from becoming public, including internal Abacus records demonstrating that Abacus knowingly relied on unusually short life expectancy estimates from Lapetus Solutions (“Lapetus”) and omitted critical facts from its public description of the Lewis & Ellis valuation report it commissioned.

Article content

Article content

Coventry Refiles Answer and Counterclaims
with Newly Unsealed Evidence

Article content

Article content

In accordance with the Court’s ruling, Coventry and Mr. Buerger yesterday refiled their Answer and Counterclaims against Abacus with the newly unsealed exhibits. These exhibits provide further support for Coventry’s claims that Abacus has misled investors and the public about its reliance on Lapetus’s life expectancy estimates as a critical input used to originate, sell, and value life settlement policies held in Abacus’s own portfolio and sold to its affiliated managed funds, including funds in which credit unions invested more than $500 million.

Article content

Unsealed Documents Show Lapetus’s Actual-to-Expected (A/E) Ratio Was Just 41.5%

Article content

Abacus has asserted in its legal filings that Lapetus’s life expectancies are “not less accurate than the estimates of any other life expectancy provider” and that “Lapetus’s estimates reported to the state of Florida are in line with other life expectancy providers.” However, the newly unsealed evidence shows that those statements were false and that Abacus knew they were false. In fact, Lapetus reported an A/E ratio of just 41.5%, meaning that fewer than half of the deaths Lapetus predicted occurred during the measurement period. By comparison, leading life expectancy providers have publicly reported A/E ratios close to 100%. This stark difference proves that Lapetus systematically underestimated life expectancies and overstated mortality risk.

Article content

Article content

Documents Show Abacus Knew Lapetus’s Life Expectancy Estimates Were Chronically Short

Article content

Other unsealed documents show that Abacus was aware of the disparity between Lapetus’s life expectancy estimates and those of other medical underwriters. In one newly unsealed email exchange, Abacus CEO Jay Jackson discussed a policy for which three established life expectancy providers produced life expectancy estimates ranging from 209 to 248 months, while Lapetus estimated just 72 months. Observing that the initial policy valuations looked “really high,” Mr. Jackson asked, “Is that because we did Lapetus only?” In another example, the newly unsealed documents reveal correspondence from experienced life settlement investors discussing their unwillingness to purchase life settlement policies from Abacus using pricing based on Lapetus because, as one investor put it, “they usually seem significantly shorter than the other more established LE providers (as I’m sure you’re well aware!).”

Article content

Lapetus’s Former CEO Said He Could No Longer Work with Abacus in Good Faith